Background: Patients with anorexia nervosa (AN) are at a high risk of renal failure. Chronic kidney disease (CKD) is often missed in these patients because the serum creatinine is a poor marker of kidney function. We studied the utility of cystatin C to detect renal failure in this population. Method: Twenty-seven AN patients were studied. Glomerular filtration rates (GFR) were measured with the chromium-51- ethylenediaminetetraacetate (51Cr-EDTA) method. We compared the ability of creatinine and cystatin C to detect stage 3 CKD (GFR below 60 ml/min) by ROC curve analysis. Results: In this cohort, there is no correlation between GFR and serum creatinine, but there is a significant correlation between cystatin C and GFR. By ROC analysis, the cystatin C concentration is better than the serum creatinine concentration for the detection of stage 3 CKD (area under the curve of 0.86 vs. 0.61, p = 0.05). Conclusion: Plasma cystatin C is better than serum creatinine in detecting stage 3 CKD in patients with AN.

1.
Yager J, Andersen AE: Clinical practice. Anorexia nervosa. N Engl J Med 2005;353:1481–1488.
2.
Herzog W, Deter HC, Fiehn W, Petzold E: Medical findings and predictors of long-term physical outcome in anorexia nervosa: a prospective, 12-year follow-up study. Psychol Med 1997;27:269–279.
3.
Brotman AW, Stern TA, Brotman DL: Renal disease and dysfunction in two patients with anorexia nervosa. J Clin Psychiatry 1986;47:433–434.
4.
Zipfel S, Lowe B, Reas DL, Deter HC, Herzog W: Long-term prognosis in anorexia nervosa: lessons from a 21-year follow-up study. Lancet 2000;355:721–722.
5.
Perrone RD, Madias NE, Levey AS: Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992;38:1933–1953.
6.
Poggio ED, Nef PC, Wang X, Greene T, Van Lente F, Dennis VW, Hall PM: Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. Am J Kidney Dis 2005;46:242–252.
7.
Brion LP, Boeck MA, Gauthier B, Nussbaum MP, Schwartz GJ: Estimation of glomerular filtration rate in anorectic adolescents. Pediatr Nephrol 1989;3:16–21.
8.
Klahr S, Tripathy K: Evaluation of renal function in malnutrition. Arch Intern Med 1966;118:322–325.
9.
Aperia A, Broberger O, Fohlin L: Renal function in anorexia nervosa. Acta Paediatr Scand 1978;67:219–224.
10.
Newman DJ: Cystatin C. Ann Clin Biochem 2002;39:89–104.
11.
Vinge E, Lindergard B, Nilsson-Ehle P, Grubb A: Relationships among serum cystatin C, serum creatinine, lean tissue mass and glomerular filtration rate in healthy adults. Scand J Clin Lab Invest 1999;59:587–592.
12.
Risch L, Huber AR: Glucocorticoids and increased serum cystatin C concentrations. Clin Chim Acta 2002;320:133–134.
13.
Brochner-Mortensen J: A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 1972;30:271–274.
14.
Brochner-Mortensen J, Rodbro P: Optimum time of blood sampling for determination of glomerular filtration rate by single-injection [51Cr]EDTA plasma clearance. Scand J Clin Lab Invest 1976;36:795–800.
15.
Castillo MJ, Scheen AJ, Jandrain B, Lefebvre PJ: Relationships between metabolic clearance rate of insulin and body mass index in a female population ranging from anorexia nervosa to severe obesity. Int J Obes Relat Metab Disord 1994;18:47–53.
16.
Delanaye P, Radermecker RP, Rorive M, Depas G, Krzesinski JM: Indexing glomerular filtration rate for body surface area in obese patients is misleading: concept and example. Nephrol Dial Transplant 2005;20:2024–2028.
17.
Turner ST, Reilly SL: Fallacy of indexing renal and systemic hemodynamic measurements for body surface area. Am J Physiol 1995;268:R978–R988.
18.
Mazzachi BC, Peake MJ, Ehrhardt V: Reference range and method comparison studies for enzymatic and Jaffe creatinine assays in plasma and serum and early morning urine. Clin Lab 2000;46:53–55.
19.
Stowe H, Lawrence D, Newman DJ, Lamb EJ: Analytical performance of a particle- enhanced nephelometric immunoassay for serum cystatin C using rate analysis. Clin Chem 2001;47:1482–1485.
20.
Galteau MM, Guyon M, Gueguen R, Siest G: Determination of serum cystatin C: biological variation and reference values. Clin Chem Lab Med 2001;39:850–857.
21.
National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1–S266.
22.
Palla B, Litt IF: Medical complications of eating disorders in adolescents. Pediatrics 1988;81:613–623.
23.
Evrard F, da Cunha MP, Lambert M, Devuyst O: Impaired osmoregulation in anorexia nervosa: a case-control study. Nephrol Dial Transplant 2004;19:3034–3039.
24.
Arimura Y, Tanaka H, Yoshida T, Shinozaki M, Yanagida T, Ando T, Hirakata H, Fujishima M: Anorexia nervosa: an important cause of chronic tubulointerstitial nephropathy. Nephrol Dial Transplant 1999;14:957–959.
25.
Schwartz WB, Relman AS: Effects of electrolyte disorders on renal structure and function. N Engl J Med 1967;276:383–389.
26.
Abrahamson M, Olafsson I, Palsdottir A, Ulvsback M, Lundwall A, Jensson O, Grubb A: Structure and expression of the human cystatin C gene. Biochem J 1990;268:287–294.
27.
Tenstad O, Roald AB, Grubb A, Aukland K: Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest 1996;56:409–414.
28.
Jacobsson B, Lignelid H, Bergerheim US: Transthyretin and cystatin C are catabolized in proximal tubular epithelial cells and the proteins are not useful as markers for renal cell carcinomas. Histopathology 1995;26:559–564.
29.
Dharnidharka VR, Kwon C, Stevens G: Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002;40:221–226.
30.
Delanaye P, Lambermont B, Chapelle JP, Gielen J, Gerard P, Rorive G: Plasmatic cystatin C for the estimation of glomerular filtration rate in intensive care units. Intensive Care Med 2004;30:980–983.
31.
Demirtas S, Bozbas A, Akbay A, Yavuz Y, Karaca L: Diagnostic value of serum cystatin C for evaluation of hepatorenal syndrome. Clin Chim Acta 2001;311:81–89.
32.
Randers E, Ivarsen P, Erlandsen EJ, Hansen EF, Aagaard NK, Bendtsen F, Vilstrup H: Plasma cystatin C as a marker of renal function in patients with liver cirrhosis. Scand J Clin Lab Invest 2002;62:129–134.
33.
Thomassen SA, Johannesen IL, Erlandsen EJ, Abrahamsen J, Randers E: Serum cystatin C as a marker of the renal function in patients with spinal cord injury. Spinal Cord 2002;40:524–528.
34.
Gerbes AL, Gulberg V, Bilzer M, Vogeser M: Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut 2002;50:106–110.
35.
den Hollander JG, Wulkan RW, Mantel MJ, Berghout A: Is cystatin C a marker of glomerular filtration rate in thyroid dysfunction? Clin Chem 2003;49:1558–1559.
36.
Jayagopal V, Keevil BG, Atkin SL, Jennings PE, Kilpatrick ES: Paradoxical changes in cystatin C and serum creatinine in patients with hypo- and hyperthyroidism. Clin Chem 2003;49:680–681.
37.
Onur S, Haas V, Bosy-Westphal A, Hauer M, Paul T, Nutzinger D, Klein H, Muller MJ: L-tri-iodothyronine is a major determinant of resting energy expenditure in underweight patients with anorexia nervosa and during weight gain. Eur J Endocrinol 2005;152:179–184.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.